Department of Family Medicine and Community Health, University of Massachusetts Medical School & Meyers Primary Care Institute, Worcester, Massachusetts, USA.
Department of Population Medicine, Harvard Medical School / Harvard Pilgrim Health Care Institute, Boston, Massachusetts, USA.
Pharmacoepidemiol Drug Saf. 2021 Aug;30(8):1066-1073. doi: 10.1002/pds.5230. Epub 2021 Mar 23.
Prescribing cascades occur when a physician prescribes a new drug to address the side-effect of another drug. Persons with Alzheimer's disease and related dementias (ADRD) are at increased risk for prescribing cascades. Our objective was to develop an approach to estimating the proportion of calcium channel blocker-diuretic (CCB-diuretic) prescribing cascades among persons with ADRD in two U.S. health plans.
We identified patients aged ≥50 on January 1, 2017, dispensed a drug to treat ADRD in the 365-days prior to/on cohort entry date. Patients had medical/pharmacy coverage for 1 year before and through cohort entry. We excluded individuals with an institutional stay encounter in the 45 days prior to cohort entry and censored patients based on: disenrollment from coverage, death, or end of data. We identified incident and prevalent CCB use in the 183-days following cohort entry, and identified subsequent incident diuretic use among incident and prevalent CCB-users within 365-days from cohort entry.
There were 121 538 eligible patients. Approximately 62% were female, with a mean age of 79.5 (SD ±8.6). Overall 2.1% of the cohort experienced a prevalent CCB-diuretic prescribing cascade with 1586 incident diuretic-users among 36 462 prevalent CCB-users (4.3%, 95% CI 4.1-4.6%]); and there were161 incident diuretic-users among 3304 incident CCB-users (4.9%, 95% CI 4.2-5.7%) (incident CCB-diuretic cascade).
We describe an approach to identify prescribing cascades in persons with ADRD, which can be used to assess the proportion of prescribing cascades in large cohorts. We determined the proportion of CCB-diuretic prescribing cascades was low.
当医生开一种新药来解决另一种药物的副作用时,就会出现处方级联。患有阿尔茨海默病和相关痴呆症(ADRD)的人发生处方级联的风险增加。我们的目的是开发一种方法来估计美国两个健康计划中患有 ADRD 的患者中钙通道阻滞剂-利尿剂(CCB-利尿剂)处方级联的比例。
我们确定了 2017 年 1 月 1 日年龄≥50 岁的患者,在队列入组日期之前/当天的 365 天内开具了治疗 ADRD 的药物。患者在队列入组前 1 年和入组期间有医疗/药房保险。我们排除了在队列入组前 45 天内有机构住院遭遇的个体,并根据以下情况对患者进行了删失:不再参保、死亡或数据结束。我们在队列入组后 183 天内确定了 CCB 的新发和现患使用情况,并在队列入组后 365 天内确定了 CCB 的新发和现患使用者中的随后新发利尿剂使用情况。
共有 121538 名符合条件的患者。约 62%为女性,平均年龄为 79.5(SD ±8.6)岁。总体而言,该队列中有 2.1%的患者经历了现患 CCB-利尿剂处方级联,在 36462 例现患 CCB 使用者中有 1586 例新发利尿剂使用者(4.3%,95%CI 4.1-4.6%);在 3304 例新发 CCB 使用者中有 161 例新发利尿剂使用者(4.9%,95%CI 4.2-5.7%)(新发 CCB-利尿剂级联)。
我们描述了一种识别患有 ADRD 的患者处方级联的方法,该方法可用于评估大队列中处方级联的比例。我们确定 CCB-利尿剂处方级联的比例较低。